Therapeutic Classification: antidotes, antirheumatics (DMARD), antiurolithics
Pharmacologic Classification: chelating agents
REMS
Absorption: Well absorbed after oral administration.
Distribution: Crosses the placenta.
Half-Life: 17.5 hr (46 days during long-term use).
ROUTE | ONSET | PEAK | DURATION |
PO (antirheumatic) | 23 mo | unknown | 13 mo |
PO (Wilsons disease) | 13 mo | unknown | unknown |
Contraindicated in:
Use Cautiously in:
Derm: pemphigus, ecchymoses, hives, itching, rash, wrinkling
EENT: blurred vision, eye pain
GI: altered taste, anorexia, cholestatic jaundice, diarrhea, dyspepsia, epigastric pain, hepatic impairment, nausea, oral ulceration, PANCREATITIS, vomiting
GU: proteinuria
Hemat: leukopenia, anemia, APLASTIC ANEMIA, eosinophilia, thrombocytopenia, thrombocytosis
MS: arthralgia, migratory polyarthritis
Neuro: myasthenia gravis syndrome
Resp: coughing, shortness of breath, wheezing
Misc: allergic reactions, GOODPASTURES SYNDROME (GLOMERULONEPHRITIS AND INTRA-ALVEOLAR HEMORRHAGE), fever, lymphadenopathy, systemic lupus erythematosuslike syndrome
Drug-drug:
Lab Test Considerations: